Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Methanococcus vannielii Putative ribosomal RNA large subunit methyltransferase H (rlmH) CSB-YP411854MNS
CSB-EP411854MNS
CSB-BP411854MNS
CSB-MP411854MNS
CSB-EP411854MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii V-type ATP synthase subunit D (atpD) CSB-YP411855MNS
CSB-EP411855MNS
CSB-BP411855MNS
CSB-MP411855MNS
CSB-EP411855MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 50S ribosomal protein L37e (rpl37e) CSB-YP411856MNS
CSB-EP411856MNS
CSB-BP411856MNS
CSB-MP411856MNS
CSB-EP411856MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Translation initiation factor 2 subunit gamma (eIF2G) CSB-YP411857MNS
CSB-EP411857MNS
CSB-BP411857MNS
CSB-MP411857MNS
CSB-EP411857MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii O-phospho-L-seryl-tRNA:Cys-tRNA synthase (Mevan_0554) CSB-YP411858MNS
CSB-EP411858MNS
CSB-BP411858MNS
CSB-MP411858MNS
CSB-EP411858MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii UPF0200 protein Mevan_0592 (Mevan_0592) CSB-YP411859MNS
CSB-EP411859MNS
CSB-BP411859MNS
CSB-MP411859MNS
CSB-EP411859MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 3-dehydroquinate dehydratase (aroD) CSB-YP411860MNS
CSB-EP411860MNS
CSB-BP411860MNS
CSB-MP411860MNS
CSB-EP411860MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 50S ribosomal protein L5P (rpl5p) CSB-YP411861MNS
CSB-EP411861MNS
CSB-BP411861MNS
CSB-MP411861MNS
CSB-EP411861MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (apgM) CSB-YP411862MNS
CSB-EP411862MNS
CSB-BP411862MNS
CSB-MP411862MNS
CSB-EP411862MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Lactaldehyde dehydrogenase (Mevan_0796) CSB-YP411863MNS
CSB-EP411863MNS
CSB-BP411863MNS
CSB-MP411863MNS
CSB-EP411863MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Tetrahydromethanopterin S-methyltransferase subunit H (mtrH) CSB-YP411864MNS
CSB-EP411864MNS
CSB-BP411864MNS
CSB-MP411864MNS
CSB-EP411864MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 6-carboxyhexanoate--CoA ligase (bioW) CSB-YP411865MNS
CSB-EP411865MNS
CSB-BP411865MNS
CSB-MP411865MNS
CSB-EP411865MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Aspartate carbamoyltransferase (pyrB) CSB-YP411866MNS
CSB-EP411866MNS
CSB-BP411866MNS
CSB-MP411866MNS
CSB-EP411866MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 6,7-dimethyl-8-ribityllumazine synthase (ribH) CSB-YP411867MNS
CSB-EP411867MNS
CSB-BP411867MNS
CSB-MP411867MNS
CSB-EP411867MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Pyridoxal biosynthesis lyase pdxS (pdxS) CSB-YP411868MNS
CSB-EP411868MNS
CSB-BP411868MNS
CSB-MP411868MNS
CSB-EP411868MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 5,10-methenyltetrahydromethanopterin hydrogenase (hmd) CSB-YP411869MNS
CSB-EP411869MNS
CSB-BP411869MNS
CSB-MP411869MNS
CSB-EP411869MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Glycine--tRNA ligase (glyS), partial CSB-YP411870MNS
CSB-EP411870MNS
CSB-BP411870MNS
CSB-MP411870MNS
CSB-EP411870MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Nascent polypeptide-associated complex protein (nac) CSB-YP411871MNS
CSB-EP411871MNS
CSB-BP411871MNS
CSB-MP411871MNS
CSB-EP411871MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Methionine--tRNA ligase (metG), partial CSB-YP411872MNS
CSB-EP411872MNS
CSB-BP411872MNS
CSB-MP411872MNS
CSB-EP411872MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Enolase (eno) CSB-YP411873MNS
CSB-EP411873MNS
CSB-BP411873MNS
CSB-MP411873MNS
CSB-EP411873MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>